Kitazawa Koji

Watanabe Mako, Kitazawa Koji, Fukuoka Hideki, Wakimasu Koichi, Inatomi Tsutomu, Yoshii Kengo et al.

This study found male gender, prior anterior uveitis, and glaucoma history significantly increase cytomegalovirus corneal endotheliitis risk after transplant. Close follow-up is crucial, especially in the first year.

Kitazawa Koji, Toda Munetoyo, Ueno Morio, Wakimasu Koichi, Tomioka Yasufumi, Uehara Asako et al.

This study found donor corneas with mature endothelial cells significantly improve long-term graft survival, even in glaucoma patients, suggesting better outcomes with careful donor selection.

Kitazawa Koji, Sotozono Chie, Kinoshita Shigeru

This abstract reviews corneal cell therapies, highlighting that Rho-associated protein kinase inhibition significantly advances cultured corneal endothelial cells, enabling injection therapy for severe corneal epithelial and endothelial diseases.

Cehofski Lasse Jørgensen, Kojima Kentaro, Terao Nobuhiro, Kitazawa Koji, Thineshkumar Sasikala, Grauslund Jakob et al.

Aqueous humor protein analysis in BRVO patients found fibronectin levels correlated with macular edema severity and visual acuity, suggesting it's a key biomarker for disease activity.

Numa Kohsaku, Imai Kojiro, Ueno Morio, Kitazawa Koji, Tanaka Hiroshi, Bush John D et al.

Cultured corneal cell injection for endothelial failure was safe and effective for 5 years, restoring corneal function and vision in most patients, offering a promising alternative to corneal transplants.

Terao Nobuhiro, Koizumi Hideki, Kojima Kentaro, Yamagishi Tetsuya, Nagata Kenji, Kitazawa Koji et al.

Chronic central serous chorioretinopathy (CSC) shows upregulated angiogenic cytokines (VEGF-A, PlGF) and inflammation (IL-6, IL-8) linked to choroidal abnormalities, suggesting angiogenesis drives chronic CSC progression.